carmustine has been researched along with Multiple Sclerosis, Chronic Progressive in 4 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Multiple Sclerosis, Chronic Progressive: A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moore, JJ | 1 |
| Massey, JC | 1 |
| Ford, CD | 1 |
| Khoo, ML | 1 |
| Zaunders, JJ | 1 |
| Hendrawan, K | 1 |
| Barnett, Y | 1 |
| Barnett, MH | 1 |
| Kyle, KA | 1 |
| Zivadinov, R | 1 |
| Ma, KC | 1 |
| Milliken, ST | 1 |
| Sutton, IJ | 1 |
| Ma, DDF | 1 |
| Xu, J | 1 |
| Ji, BX | 1 |
| Su, L | 1 |
| Dong, HQ | 1 |
| Sun, WL | 1 |
| Wan, SG | 1 |
| Liu, YO | 1 |
| Zhang, P | 1 |
| Liu, CY | 1 |
| Loh, SM | 1 |
| Ratnagopal, P | 1 |
| Tan, HC | 1 |
| Goh, YT | 1 |
| Koh, BC | 1 |
| Koh, LP | 1 |
| Linn, YC | 1 |
| Hwang, WY | 1 |
| Mancardi, GL | 1 |
| Saccardi, R | 1 |
| Filippi, M | 1 |
| Gualandi, F | 1 |
| Murialdo, A | 1 |
| Inglese, M | 1 |
| Marrosu, MG | 1 |
| Meucci, G | 1 |
| Massacesi, L | 1 |
| Lugaresi, A | 1 |
| Pagliai, F | 1 |
| Sormani, MP | 1 |
| Sardanelli, F | 1 |
| Marmont, A | 1 |
4 trials available for carmustine and Multiple Sclerosis, Chronic Progressive
| Article | Year |
|---|---|
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; | 2019 |
Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; China; Cytarabine; Disease-Free S | 2011 |
Successful autologous hematopoietic stem cell transplantations for severe multiple sclerosis with fludarabine and cyclophosphamide conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Fem | 2006 |
Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Eto | 2001 |